FMT for Multidrug Resistant Organism Reversal

February 8, 2021 updated by: Washington University School of Medicine

Use of Fecal Microbiota Transplantation (FMT) to Reverse Multi-Drug Resistant Organism Carriage

This proposed protocol involves the use of the fecal microbiota transplantation (FMT) to suppress or reverse colonization with multidrug resistant organisms (MDRO) in subjects with recurrent MDRO infections due to organisms of likely enteric origin.

FMT will be performed on subjects with a history of at least three recurrent infections due to MDRO; at least two recurrent, severe infections due to MDRO requiring hospitalization; or at least two recurrent infections due to MDRO for which only antimicrobials with rate limiting toxicities are available.

The objective of this protocol is to determine if fecal microbiota transplantation (FMT) will be able to prevent additional recurrences of infections due to MDRO by suppressing or reversing enteric colonization with MDRO.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a prospective pilot study of fecal microbiota transplantation in patients with a history of recurrent MDRO infections. Subjects who meet inclusion/exclusion criteria and provide written, informed consent will provide a pre-FMT stool sample. The FMT will be administered by enema in the outpatient setting by trained personnel. Patients will provide stool samples 30 days, 6 months, and 12 months post-FMT. The subjects will also be monitored for potential adverse events, recurrence of MDRO infections, infections that may be related to FMT, and worsening of existing comorbidities or development of new comorbidities.

Study Type

Interventional

Enrollment (Actual)

1

Phase

  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria will include:

  • Age ≥18 years old.
  • Outpatient status at time of FMT.
  • History of at least three recurrent infections due to an MDRO; at least two recurrent, severe infections due to MDRO requiring hospitalization; or at least two recurrent infections due to MDRO for which only antimicrobials with rate limiting toxicities (see above) are available AND the MDRO is likely of enteric origin. Only MDROs of likely enteric origin will be included.
  • Be without active infection due to the MDRO at the time of FMT.
  • Not be receiving antimicrobials (therapeutic or suppressive) within 48 hours of FMT.

Exclusion criteria will include:

  • Subjects <18 years old.
  • Subjects unable to be seen as an outpatient.
  • Use of enteral or systemic antimicrobials at time of FMT.
  • Planned use of enteral or systemic antimicrobials up to 6 months post-FMT.
  • Pregnancy or inability/unwillingness to use contraceptives.
  • Recent intra-abdominal surgery
  • Short gut syndrome
  • Gastrointestinal motility disorders
  • Use of medications that affect intestinal motility an inability to cease using those medications at the time of FMT.
  • Post-allogeneic hematopoietic stem cell transplant recipients with previous or current gastrointestinal graft versus host disease.
  • ANC <500/mm3
  • HIV+ and not well controlled on antiretroviral therapy, or CD4+ <200/ mm3
  • At increased risk for peritonitis: presence of intra-abdominal devices, receiving peritoneal dialysis, or ascites.
  • Any acute illness
  • Recurrent C. difficile infection.
  • Unlikely to survive for 3 months.
  • Investigator feels the risks of FMT outweigh potential benefit, including other conditions or medications that the investigator determines puts the subject at greater risk from FMT.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fecal microbiota transplantation
Subjects will receive 150mL of fecal microbiota product via enema.
Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
Other Names:
  • FMT
  • stool transplant

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events)
Time Frame: 12 months post-FMT
Incidence and severity of solicited and serious adverse events within 12 months of FMT.
12 months post-FMT

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MDRO Infection Status Post-FMT (Number of Subjects With MDRO Infections)
Time Frame: 30 days, 6 months, and 12 months post-FMT
Number of subjects with MDRO infections 30 days, 6 months, and 12 months post-FMT.
30 days, 6 months, and 12 months post-FMT

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Erik R Dubberke, MD, MSPH, Washington University School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Actual)

July 31, 2020

Study Completion (Actual)

July 31, 2020

Study Registration Dates

First Submitted

December 4, 2014

First Submitted That Met QC Criteria

December 8, 2014

First Posted (Estimate)

December 9, 2014

Study Record Updates

Last Update Posted (Actual)

February 24, 2021

Last Update Submitted That Met QC Criteria

February 8, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 201506131

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.